The Craneware Board has declared an interim dividend of 13.5p (16.87 cents) per ordinary share, payable on 17 April 2025 to those shareholders on the register as at 21 March 2025 (FY24 Interim dividend 13.0p). The ex-dividend date is 20 March 2025.
Other financial highlights include:
Strong financial performance, delivering record interim Group revenue and Adjusted EBITDA, with a return to double-digit growth rates
18% growth in adjusted basic EPS and increased operating cash conversion resulted in Group cash reserves growing to $72.2m (H1 FY24: $63.9m) and a reduction in bank debt to $31.6m (H1 FY24: $59.2m), in addition to funding dividends
Future growth remains underpinned by high levels of ARR and strong customer retention at above 90% across all measures
Continued expansion and cross-sales to all hospital strata, with Net Revenue Retention ("NRR") greater than 100%
First major customer contract executed via the Azure Marketplace, as part of the previously announced alliance with Microsoft
Continued investment in R&D and innovation to capitalise on growing market opportunity
Development of AI enhancements to existing offerings in conjunction with Microsoft, including the launch post period end of Trisus® Assist, an AI-powered personal assistant providing workflow help, healthcare coding research and persona-based compliance prompt engineering
Further strengthening of the Board through the appointment of two experienced US healthcare executives as Non-Executive Directors
Trisus® Chargemaster ranked first in the "2025 Best In KLAS Awards: Software & Services" for the 14th time, underlining Craneware's long-standing position as a healthcare technology industry leader
